Difference between revisions of "Team:ASIJ Tokyo"

 
(2 intermediate revisions by one other user not shown)
Line 1: Line 1:
 
{{ASIJ_Tokyo/CSS}}
 
{{ASIJ_Tokyo/CSS}}
 
{{:Team:ASIJ_Tokyo/bar}}
 
{{:Team:ASIJ_Tokyo/bar}}
−
 
  
 
<html>
 
<html>
Line 31: Line 30:
 
}
 
}
  
 +
footer {
 +
border-top: 2px dotted #fff;
 +
margin-top: 10%;
 +
}
 +
 +
#footer_logo {
 +
height: 130px;
 +
display: block;
 +
margin: 25px;
 +
margin-left: auto;
 +
margin-right: auto;
 +
}
 +
 +
footer p{
 +
float: right;
 +
color: #88C1EF;
 +
}
 +
 +
footer p a{
 +
color: #88C1EF;
 +
}
  
 
    
 
    
Line 122: Line 142:
 
</tr>
 
</tr>
 
<tr>
 
<tr>
−
<td id="subtitle"><h2> Using Stem Cell and CRISPR Technology to Combat Alpha-1 Antitrypsin Deficiency </h2></td>
+
<td id="subtitle"><h2> Using CRISPR Technology to Combat Alpha-1 Antitrypsin Deficiency </h2></td>
 
</tr>
 
</tr>
 
</table>
 
</table>
 
<div id="abstract">
 
<div id="abstract">
 
<h3> ABSTRACT </h3>
 
<h3> ABSTRACT </h3>
−
<p> Alpha-1 Antitrypsin deficiency is a common genetic disorder -- the defective gene for which is carried by 1 in 25 people -- which arises from a single base pair mutation in the SERPINA1 gene, resulting in the production of a form of antitrypsin prone to polymerization. The mutated antitrypsin then builds up in liver cells and is unable to inhibit proteases in the lungs, leading to damage in both. Using CRISPR-Cas9 technology, we aimed to fix the error in SERPINA1 so that proper antitrypsin can be produced. We will show proof of concept in E. Coli cells using osmy secretion tags and GFP as a reporter. We hope to design a liver organ bud using IPS cell technology to deliver function A1AT through collaboration with Dr. Kagimoto of Healios Japan KK.
+
<p> Alpha-1 antitrypsin (A1AT) deficiency is a genetic disorder that arises from a single base pair mutation in the SERPINA gene. The disease results in the production of a form of A1AT prone to polymerization, which builds up in liver cells and is unable to inhibit proteases in the lungs. The lack of antitrypsin leads to damage in both the liver and the lungs. Using CRISPR-Cas9 technology, we attempted to fix the point mutation in SERPINA1 so that proper antitrypsin can be produced. We will test our system in E. Coli cells using histidine tags, osmY secretion tags, and GFP as a reporter. We hope to design a liver organ bud using iPS cell technology to deliver functional antitrypsin through collaboration with Dr. Kagimoto of Healios Japan KK.
 
</div>
 
</div>
 +
 +
        <footer>
 +
  <img id=footer_logo src="https://static.igem.org/mediawiki/2018/4/4b/T--ASIJ_Tokyo--TeamLogo.png" alt="iGEMlogo">
 +
<h6>Icon used in the background made by <a href="https://www.flaticon.com/authors/ddara">dDara</a>from <a href="www.flaticon.com">www.flaticon.com</a></h6>
 +
        </footer>
  
 
</div>
 
</div>
Line 134: Line 159:
 
</body>
 
</body>
  
−
{{ASIJ_Tokyo/footer}}
 
 
</html>
 
</html>

Latest revision as of 04:16, 17 October 2018

liver

A1-AT
deLIVERy

Using CRISPR Technology to Combat Alpha-1 Antitrypsin Deficiency

ABSTRACT

Alpha-1 antitrypsin (A1AT) deficiency is a genetic disorder that arises from a single base pair mutation in the SERPINA gene. The disease results in the production of a form of A1AT prone to polymerization, which builds up in liver cells and is unable to inhibit proteases in the lungs. The lack of antitrypsin leads to damage in both the liver and the lungs. Using CRISPR-Cas9 technology, we attempted to fix the point mutation in SERPINA1 so that proper antitrypsin can be produced. We will test our system in E. Coli cells using histidine tags, osmY secretion tags, and GFP as a reporter. We hope to design a liver organ bud using iPS cell technology to deliver functional antitrypsin through collaboration with Dr. Kagimoto of Healios Japan KK.